TABLE 2.

Effect of broad-spectrum MMP inhibitors on the outcome in models of sepsis and septic shock and after LPS injection in rodents

Model	Inhibitor(s)	Outcome(s)a	Reference
Bolus LPS i.v.	Tetracycline	Protection against LPS-induced mortality and inflammatory lesions	134
Bolus LPS i.p.	Tetracycline/doxycycline	Improved survival; no secretion of TNF, IL-1β, or NO in the blood	89
	Marimastat	Inhibition of TNF production but only slight delay in mortality	148
	GM-6001	Attenuated TNF response	139
	Ro 31-9790/doxycycline	Improved cardiac function and less-elevated MMP-9 activity	67
CLP	CMT-3/hydroxamate	Less mortality; less-elevated GOT, GPT, NO, and MMP-9 levels; and reduced gelatinase activity	79
	CMT-3	Reduced mortality and lung pathology, less-elevated MMP-2 and MMP-9 levels in lung	142
	CMT-3	Improved survival was associated with a significant improvement in lung pathology	39
LPS intratracheally	CMT-3	Less neutrophil recruitment and goblet cell metaplasia, lower expression levels of epithelial growth factor receptor and MMP-9	59
	Corticosteroids	Reduced infiltration of neutrophils and reduced activity of MMP-2 and MMP-9	22
LPS intracerebrally	Minocycline, BB-1101, BB-94	Reduced blood-brain barrier injury by blocking production of MMP-9	126
	BB-1101	Reduced blood-brain barrier opening, associated with a significant drop in MMP-2 and MMP-9	94

^aGOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase.